Home
HomeChat
Markets
AlertsCalendarScreenerCharts
Portfolio
WatchlistsPortfolioFiles
Account
Docs
Sign upJoinLog inLogin

Jaguar Health, Inc. (JAGX) stock profile

Jaguar Health, Inc. is a commercial-stage pharmaceutical company that focuses on developing prescription medicines for people and animals suffering from gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments: Human Health and Animal Health. It markets Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The company also develops Crofelemer for multiple possible follow-on indications, including cancer therapy-related diarrhea, orphan-drug indications for symptomatic relief of diarrhea in infants and children with congenital diarrheal disorders, for adult and pediatric patients with short bowel syndrome and intestinal failure, supportive care for diarrhea relief in inflammatory bowel diseases, diarrhea-predominant irritable bowel syndrome, and idiopathic or functional diarrhea. Additionally, it develops lechlemer, a second-generation anti-secretory agent for cholera, and Canalevia, an oral plant-based drug candidate to treat chemotherapy-induced diarrhea in dogs and exercise-induced diarrhea in dogs. Jaguar Health, Inc. was founded in 2013 and is headquartered in San Francisco, California.

Key facts

SymbolJAGX
ExchangeNASDAQ
SectorHealthcare
IndustryBiotechnology
CEOLisa A. Conte
Employees49
HeadquartersSan Francisco, CA, US
IPO2015-05-12
Websitejaguar.health

Explore JAGX on Vantafin

  • Jaguar Health, Inc. Overview
  • Jaguar Health, Inc. Financials
  • Jaguar Health, Inc. News
  • Jaguar Health, Inc. Events
  • Jaguar Health, Inc. SEC filings
  • Jaguar Health, Inc. Insider transactions
  • Jaguar Health, Inc. Transcripts

Frequently asked questions

What does Jaguar Health, Inc. (JAGX) do?
Jaguar Health, Inc. is a commercial-stage pharmaceutical company that focuses on developing prescription medicines for people and animals suffering from gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments: Human Health and Animal Health. It markets Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The company also develops Crofelemer for multiple possible follow-on indications, including cancer therapy-related diarrhea, orphan-drug indications for symptomatic relief of diarrhea in infants and children with congenital diarrheal disorders, for adult and pediatric patients with short bowel syndrome and intestinal failure, supportive care for diarrhea relief in inflammatory bowel diseases, diarrhea-predominant irritable bowel syndrome, and idiopathic or functional diarrhea. Additionally, it develops lechlemer, a second-generation anti-secretory agent for cholera, and Canalevia, an oral plant-based drug candidate to treat chemotherapy-induced diarrhea in dogs and exercise-induced diarrhea in dogs. Jaguar Health, Inc. was founded in 2013 and is headquartered in San Francisco, California.
Where is JAGX stock listed?
Jaguar Health, Inc. trades under the ticker JAGX on NASDAQ.
How can I research JAGX's financials and filings?
Vantafin provides Jaguar Health, Inc.'s income statement, balance sheet and cash-flow data, SEC filings, earnings-call transcripts, and insider & institutional ownership on the JAGX profile.